血生物标志物的变化使用免疫磁性还原试验区分阿尔茨海默病的临床阶段
Shu-Ping Chao1,2, Wei-Che Lin3, Cheng-Hsien Lu4
1Dementia Center, Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Journal of Alzheimer's disease : JAD
|November 14, 2024
概括
免疫磁性还原试验显示了阿尔茨海默病的鲜明的血生物标志物模式. 随着疾病的进展,粉样蛋白-β 1-40 减少,而粉样蛋白-β 1-42 和总蛋白增加.
科学领域:
- 生物标志物发现发现
- 神经退行性疾病 神经退行性疾病
- 临床化学 临床化学
背景情况:
- 免疫磁降解 (IMR) 用于量化等离子体生物标志物.
- 关键的生物标志物包括粉样β1-40 (Aβ1-40),粉样β1-42 (Aβ1-42) 和总蛋白 (T-Tau).
- 这些生物标志物在认知正常对照 (NC),记忆力轻度认知障碍 (aMCI) 和阿尔茨海默氏症痴呆症 (ADD) 患者中进行评估.
研究的目的:
- 综合和分析有关血Aβ1-40,Aβ1-42和T-Tau的IMR测定性能现有数据.
- 评估这些生物标志物的实用性,以区分NC,aMCI和ADD.
主要方法:
- 使用PubMed和Embase进行了全面的文献搜索.
- 分析了30项研究 (25项已发表,2项会议,3项未发表) 的数据.
- 包括1189名NC,544名aMCI和853名ADD受试者.
主要成果:
- 血Aβ1-40从NC显著降低到aMCI,在ADD中没有显著差异.
- 血Aβ1-42从NC显著增加到aMCI,ADD没有显著差异.
- 血T-Tau从NC显著增加到aMCI,并进一步增加到ADD,表明疾病严重程度的依赖.
结论:
- 血Aβ1-40,Aβ1-42和T-Tau水平可以区分NC,aMCI和ADD.
- 血T-Tau水平与阿尔茨海默病的严重程度有明显的相关性.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.阿尔茨海默病痴呆症阿尔茨海默病痴呆症缓慢的认知障碍 缓慢的认知障碍粉样蛋白是什么 粉样蛋白免疫磁性降低 免疫磁性降低血生物标志物 血生物标志物蛋白质是一种蛋白质.更多相关视频
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.2K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.2K
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165